- Home
- ORLA vs GERN Comparison
ORLA vs GERN Comparison
Compare ORLA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORLA
- GERN
- Stock Information
- Founded
- ORLA 2007
- GERN 1990
- Country
- ORLA Canada
- GERN United States
- Employees
- ORLA N/A
- GERN N/A
- Industry
- ORLA Precious Metals
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- ORLA Basic Materials
- GERN Health Care
- Exchange
- ORLA Nasdaq
- GERN Nasdaq
- Market Cap
- ORLA 1.9B
- GERN 1.5B
- IPO Year
- ORLA N/A
- GERN 1996
- Fundamental
- Price
- ORLA $6.70
- GERN $2.57
- Analyst Decision
- ORLA Buy
- GERN Strong Buy
- Analyst Count
- ORLA 2
- GERN 11
- Target Price
- ORLA $6.13
- GERN $6.82
- AVG Volume (30 Days)
- ORLA 765.0K
- GERN 12.4M
- Earning Date
- ORLA 03-18-2025
- GERN 02-26-2025
- Dividend Yield
- ORLA N/A
- GERN N/A
- EPS Growth
- ORLA N/A
- GERN N/A
- EPS
- ORLA 0.01
- GERN N/A
- Revenue
- ORLA $314,101,000.00
- GERN $29,480,000.00
- Revenue This Year
- ORLA $44.99
- GERN $31,918.56
- Revenue Next Year
- ORLA $141.65
- GERN $289.41
- P/E Ratio
- ORLA $485.14
- GERN N/A
- Revenue Growth
- ORLA 38.09
- GERN 9199.68
- 52 Week Low
- ORLA $3.16
- GERN $1.64
- 52 Week High
- ORLA $7.62
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- ORLA 53.75
- GERN 31.98
- Support Level
- ORLA $6.67
- GERN $2.49
- Resistance Level
- ORLA $7.24
- GERN $2.84
- Average True Range (ATR)
- ORLA 0.31
- GERN 0.15
- MACD
- ORLA -0.02
- GERN -0.01
- Stochastic Oscillator
- ORLA 42.50
- GERN 13.33
About ORLA Orla Mining Ltd.
Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Mexico, and the South Railroad and Lewis gold projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.